Better Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 09, 2023
08 Novembre 2023 - 1:30PM
Business Wire
Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in
developing prescription digital therapeutics to treat
cardiometabolic diseases, today announced it will release its third
quarter 2023 financial results before the market opens on Thursday,
November 09, 2023. Management will host a conference call and
webcast to provide a business update at 8:30 a.m. ET / 5:30 a.m. PT
on Thursday, November 09, 2023.
To access the conference call, please register at:
https://register.vevent.com/register/BI7ccccb1e37c44102b4f5ce26d785604d.
Upon registering, each participant will be provided with call
details and access codes. All participants are encouraged to join
10 minutes prior to the start time. The live webcast may be
accessed by visiting the event link at:
https://edge.media-server.com/mmc/p/dk6kxzaw. A replay of the
webcast may be accessed from the Presentations & Events page in
the Investors section of the Better Therapeutics corporate website
at: https://investors.bettertx.com.
About Better Therapeutics
Better Therapeutics is a prescription digital therapeutics
company developing a novel form of cognitive behavioral therapy to
address underlying factors that sustain or worsen cardiometabolic
diseases. The Company has developed a proprietary platform for the
development of FDA-regulated, software-based solutions and in July
2023 received FDA authorization for AspyreRxTM to treat adults with
type 2 diabetes. The CBT delivered by Better Therapeutics’ PDT is
designed to enable changes in neural pathways of the brain so
lasting changes in behavior become possible. Addressing the
underlying causes of these diseases has the potential to
dramatically improve patient health while lowering healthcare
costs. Better Therapeutics’ clinically validated mobile
applications are intended to be prescribed by physicians and
reimbursed like traditional medicines.
For more information visit: bettertx.com and aspyrerx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231108041737/en/
Investor Relations: Mark Heinen IR@bettertx.com
Media Enquiries: Emma Williams
emma.williams@bettertx.com
Grafico Azioni Better Therapeutics (NASDAQ:BTTX)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Better Therapeutics (NASDAQ:BTTX)
Storico
Da Mag 2023 a Mag 2024